Back to Journals » Cancer Management and Research » Volume 10

The role of biosimilars in value-based oncology care

Authors Patel KB, Arantes Jr LH, Tang WY, Fung S

Received 31 January 2018

Accepted for publication 7 May 2018

Published 17 October 2018 Volume 2018:10 Pages 4591—4602

DOI https://doi.org/10.2147/CMAR.S164201

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Professor Nakshatri


Kashyap B Patel,1 Luiz H Arantes Jr,2 Wing Yu Tang,3 Selwyn Fung4

1Carolina Blood and Cancer Care, Rock Hill, SC, USA; 2Biosimilars Global Medical Affairs, Pfizer Essential Health, Pfizer Inc. New York, NY, USA; 3Health Economics and Outcomes Research, Pfizer Health & Impact, Pfizer Essential Health, Pfizer Inc. New York, NY, USA; 4Pfizer Essential Health Research & Development, Pfizer Inc. New York, NY, USA

Abstract:
Biopharmaceuticals (biologics) represent one of the fastest growing sectors of cancer treatment. They are recommended for treating underlying cancer and as supportive care for management of treatment side effects. Given the high costs of cancer care and the need to balance health care provision and associated budgets, patient access and value are the subject of discussion and debate in the USA and globally. As the costs of biologics are high, biosimilars offer the potential of greater choice and value, increased patient access to treatment, and the potential for improved outcomes. Value-based care aims to improve the quality of care, while containing costs. The Centers for Medicare & Medicaid Services (CMS) has developed value-based care programs as alternatives to fee-for-service reimbursement, including in oncology, that reward health care providers with incentive payments for improving the quality of care they provide. It is anticipated that CMS payments in oncology care will be increasingly tied to measured performance. This review provides an overview of value-based care models in oncology with a focus on CMS programs and discusses the contribution of biosimilars to CMS value-based care objectives. Biosimilars may provide an important tool for providers participating in value-based care initiatives, resulting in cost savings and efficiencies in the delivery of high-value care through expanded use of biologic treatment and supportive care agents during episodes of cancer care.

Keywords: biologics, biosimilars, oncology, patient access, value-based care, supportive care

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]